Hologic Inc. is a global medical technology company focused on improving women's health through the development and delivery of innovative products and solutions. The company specializes in diagnostic, surgical, and medical imaging systems, with a particular emphasis on breast health, cervical health, and skeletal health. Hologic's offerings include advanced molecular diagnostics, imaging systems for breast cancer detection, and various surgical instruments and techniques that enhance patient care. With a commitment to advancing health outcomes for women, Hologic actively invests in research and development to address unmet medical needs and improve access to vital healthcare solutions. Read More
Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations.
However, they face intense competition from scaled industry giants and can be disrupted by new innovative players vying for a slice of the pie.
Medical technology company Hologic (NASDAQ:HOLX) reported Q2 CY2025 results topping the market’s revenue expectations, with sales up 1.2% year on year to $1.02 billion. The company expects next quarter’s revenue to be around $1.04 billion, close to analysts’ estimates. Its non-GAAP profit of $1.08 per share was 2.7% above analysts’ consensus estimates.
After the conclusion of the US market's regular session on Wednesday, let's examine the after-hours session and unveil the notable S&P500 performers among the top gainers and losers.
Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor.
The key risk, however, is that these stocks are usually cheap for a reason – five cents for a piece of fruit may seem like a great deal until you find out it’s rotten.
Hologic, Inc. (Nasdaq: HOLX) announced today that the Company plans to release its financial results for the third quarter of fiscal 2025 on Wednesday, July 30, after the market closes. In conjunction with the release, management will host a conference call that day at 4:30 p.m. Eastern Time.
Hologic’s first quarter saw results broadly in line with Wall Street expectations, yet the company’s shares declined after the report as investors digested softer demand in select segments and international pressures. Management pointed to strong recurring revenue growth—especially in breast health services—as a stabilizing factor, while acknowledging that tariff costs and funding cuts in Africa weighed on diagnostic sales. CEO Steve MacMillan highlighted, “our Diagnostics business continued to grow nicely, despite steep declines in our Africa business following funding cuts,” and noted that recurring revenue now makes up a substantial portion of total sales.
Generating cash is essential for any business, but not all cash-rich companies are great investments.
Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.
A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance.
Investors who prioritize stability may miss out on higher-reward opportunities elsewhere.
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability.
But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition.
Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look at Hologic (NASDAQ:HOLX) and its peers.
Hologic declined a $16 billion buyout bid from TPG and Blackstone as it faces falling shares and tariff-related headwinds, leaving room for deal talks to potentially resume.
